Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05504772
Other study ID # ZERO2
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date December 16, 2022
Est. completion date July 2030

Study information

Verified date February 2023
Source Australian & New Zealand Children's Haematology/Oncology Group
Contact National Study Coordinator
Phone +61 2 9382 3102
Email SCHN-ZERO2@health.nsw.gov.au
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

To improve outcomes for childhood cancer patients through the implementation of precision medicine.


Description:

Through the pilot TARGET and national PRISM trials the feasibility and benefits of using comprehensive molecular profiling and preclinical drug testing in real time for high-risk (HR) patients has been demonstrated. However, the role of precision medicine, especially in facilitating diagnosis and risk stratification in non-HR childhood cancers has not been studied. Integrative tumor-germline whole genome sequencing (WGS) analysis has the potential to advance our understanding of cancer predisposition. In this study, the ZERO platform will be extended to all children with cancer in Australia and New Zealand, evaluating the benefits of precision medicine in different childhood cancer types and risk groups.


Recruitment information / eligibility

Status Recruiting
Enrollment 3500
Est. completion date July 2030
Est. primary completion date July 2025
Accepts healthy volunteers No
Gender All
Age group 0 Years to 25 Years
Eligibility Inclusion Criteria: 1. Age < 18 years Note: Individual patients aged 19 - 25 years old with a pediatric cancer, e.g., neuroblastoma, may be enrolled after discussion with, and at the discretion of, the Study Chair or their delegate. 2. Life expectancy >6 weeks at time of enrolment 3. Consent i. Signed and dated informed consent for study enrolment from participant aged = 18 years or from parent/guardian of participant aged <18 years. ii. Separate signed and dated informed consent for understanding the role of germline testing and choice for the return of germline results.

Study Design


Intervention

Genetic:
Whole Genome Sequencing
Each tumor sample will be sequenced and analyzed in parallel with its matched normal (germline DNA from the same patient) to enable the identification of somatic aberrations.
RNA seq
Results will be used for bioinformatics analysis for fusion transcripts and gene expression.
DNA Methylation
Genome-wide assessment of DNA methylation will be conducted on all samples where possible.
Targeted Panel Sequencing
Targeted panel sequencing may be performed: When WGS is not feasible or appropriate, e.g., insufficient DNA from fresh or frozen sample or only Formalin-Fixed Paraffin-Embedded (FFPE) material is available When mosaicism is suspected When indicated for a disease type
High Throughput Sequencing (in vitro)
High throughput drug screening will be attempted for tumors from Cohort 1 (high-risk cancers with survival <30%) and selected tumor types.
Patient Derived Xenograft (PDX)(in vivo)
In vivo drug testing in patient derived xenograft (PDX) will be attempted for tumors from Cohort 1 (high-risk cancers) and selected tumor types.
Other:
Liquid Biopsy
Liquid biopsy will be investigated as a non-invasive method for diagnosis of tumors that are difficult to biopsy directly, understanding tumor heterogeneity, monitoring of treatment response, and detection of minimal residual disease (MRD)/relapse in leukemia, solid and CNS tumors.

Locations

Country Name City State
Australia Women's and Children's Hospital Adelaide
Australia Queensland Children's Hospital Brisbane
Australia Royal Hobart Hospital Hobart
Australia Monash Children's Hospital Melbourne
Australia Royal Children's Hospital Melbourne
Australia John Hunter Children's Hospital Newcastle
Australia Perth Children's Hospital Perth
Australia Sydney Children's Hospital, Randwick Sydney
Australia The Children's Hospital at Westmead Sydney

Sponsors (4)

Lead Sponsor Collaborator
Australian & New Zealand Children's Haematology/Oncology Group Children's Cancer Institute (CCI), Medical Research Future Fund, Minderoo Foundation

Country where clinical trial is conducted

Australia, 

Outcome

Type Measure Description Time frame Safety issue
Primary Utility of recommended personalized therapy for HR childhood cancer patients. Disease control rate (stable disease + partial response + complete response) in HR patients who have received recommended personalized therapy which are molecularly and/or preclinically directed 5 years
Primary Utility of recommended personalized therapy for non-HR childhood cancer patients. The proportion of non-HR patients for whom the disease specific, clinically relevant, virtual molecular panel provides additional or equivalent results for diagnosis and risk stratification when compared with routine diagnostic tests. 5 years
Secondary Utility of pre-defined virtual molecular panel for non-HR childhood cancer patients. The proportion of non-HR patients for whom a pre-defined virtual molecular panel; leads to a streamline molecular report issued within 4 weeks from receipt of samples, changes or refines the initial histopathological diagnosis, changes or refines risk stratification at diagnosis, changes or refines treatment at diagnosis and/or facilitates enrolment in clinical trials requiring prior molecular studies. 5 years
Secondary Utility of comprehensive precision medicine for patients with rare tumors in childhood. Proportion of rare cancer cohort patients for which comprehensive precision medicine improves diagnosis, identifies at least one therapeutic target or facilitates improvement in therapy within a clinically relevant timeframe. 5 years
Secondary Utility of Molecular Tumour Board (MTB) recommendation tier system for HR childhood cancer patients. Evaluation of the correlation of MTB recommendation tier to treatment outcome, clinician rated value of MTB recommendation tier in facilitating therapeutic decision and drug access and proportion of HR patients for which the MTB recommendation improves diagnosis, risk stratification or facilitates improvement in therapy within a clinically relevant timeframe. 5 years
Secondary Utility of preclinical testing in HR childhood cancer patients. Evaluation of proportion of tumors where in vitro sensitivity testing can be successfully performed compared with PRISM trial, turnaround time for preclinical in vitro and in vivo drug testing, proportion of tumors where in vitro drug sensitivity identifies additional molecular drivers and proportion of patients for whom preclinical testing:
i. Facilitates therapeutic decision ii. Identifies additional therapeutic options in patients for whom genomic profiling did not identify molecular targets iii. Predicts clinical outcome
5 years
Secondary Clinical utility of germline WGS in patients with childhood cancers. Evaluation of;
Proportion of HR and non-HR patients with a reportable germline finding (i. For whom the result was not previously known ii. For whom the results would have been missed using current clinical testing criteria)
Proportion of patients for whom medical management for the current cancer and future cancer risk has been altered based on the germline findings
5 years
Secondary Treatment outcome in HR childhood cancer patients who have received recommended personalised therapy which are molecularly and/or preclinically directed. Evaluation of;
Objective response in patients who have received single agent versus combination personalized therapy
Disease control (stable disease + partial response + complete response) in patients who have received a single agent versus combination personalized therapy
Progression-free interval (PFI) ratio: PFI personalized therapy : PFI conventional therapy
Difference in outcome between patients have received recommended personalised therapy and those who did not (i. Proportion of patients without progression or death at 6 and 12 months between the two groups ii. Difference in progression-free and overall survival between the two groups)
5 years
See also
  Status Clinical Trial Phase
Enrolling by invitation NCT04202094 - Fertility in Young Adults Who Did (Not) Store Testicular Tissue Before a Treatment Leading to Fertility Problems N/A
Active, not recruiting NCT03336931 - PRecISion Medicine for Children With Cancer
Not yet recruiting NCT05048771 - Fertility and Temporality in Pediatric Oncology
Completed NCT05982379 - Motivation Program for Children With Cancer N/A
Completed NCT04066218 - Sexual Function Screening in Childhood Cancer Survivors
Completed NCT03934060 - Strength Training and ADLs in Childhood Leukemia and Lymphoma Patients N/A
Active, not recruiting NCT03938324 - Peer i-Coaching for Activated Self-Management Optimization in Adolescents and Young Adults With Chronic Conditions N/A
Active, not recruiting NCT04032743 - Risk Factors and Treatment Outcome of Oncology Children Hospitalized in the Intensive Care Unit Due to Sepsis
Active, not recruiting NCT04328350 - Social Experiences of Adolescents and Young Adults With Cancer
Not yet recruiting NCT05457153 - Technology-Based Well-Being Process Program (WEBEPROP) for Children and Adolescents in Palliative Care N/A
Recruiting NCT05641961 - Mobile App to Help Survivors of Childhood Cancer Navigate Long-Term Follow-Up Care N/A
Completed NCT06179914 - Resilience Models in Adolescence and Youth With Cancer in Taiwan
Completed NCT03951246 - Cognitive and Motor Training in Pediatric Posterior Fossa Tumor Survivors N/A
Not yet recruiting NCT04902313 - Cultivating Resilience in Oncology Practice N/A
Completed NCT03160768 - Feasibility of Isolating P16 Expression
Recruiting NCT06411704 - Remote Exercise Video Adaptations to Maximize Physical Activity in Childhood Cancer
Recruiting NCT06053268 - Mindfulness Interventions to Improve Health Activation, Coping, and Stress Among Childhood Cancer Survivors N/A
Withdrawn NCT02130934 - Cardiac 3D MRI in Pediatric Cancer Patients N/A
Completed NCT02216604 - Exercise in Pediatric Cancer Patient Undergoing Anti-Cancer Treatment N/A
Recruiting NCT03852758 - Green Exercise for Cancer - Creating Opportunities for Survivors N/A